Active Surveillance versus Spontaneous Reporting for First-Line Antiretroviral Medicines in Namibia: A Cost-Utility Analysis (Q39675654)

13 September 2017

title

Active Surveillance versus Spontaneous Reporting for First-Line Antiretroviral Medicines in Namibia: A Cost-Utility Analysis (English)

1 reference

13 September 2017

0 references

anti-retroviral agent

0 references

6

Joseph B Babigumira

1 reference

13 September 2017

Marita Mann

1

1 reference

13 September 2017

Assegid Mengistu

2

1 reference

13 September 2017

Johannes Gaeseb

3

1 reference

13 September 2017

Evans Sagwa

4

1 reference

13 September 2017

Greatjoy Mazibuko

5

1 reference

13 September 2017

Louis P Garrison

7

1 reference

13 September 2017

Andy Stergachis

8

1 reference

13 September 2017

publication date

17 June 2016

1 reference

13 September 2017

1 reference

13 September 2017

volume

39

1 reference

13 September 2017

issue

9

1 reference

13 September 2017

page(s)

859-872

1 reference

The impact of specific HIV treatment-related adverse events on adherence to antiretroviral therapy: a systematic review and meta-analysis

13 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007/S40264-016-0432-Y

Addressing gaps in pharmacovigilance practices in the antiretroviral therapy program in the Eastern Cape Province, South Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40264-016-0432-Y

WHO strategy for collecting safety data in public health programmes: complementing spontaneous reporting systems.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40264-016-0432-Y

Pharmacovigilance and global HIV/AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40264-016-0432-Y

The risks of risk aversion in drug regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40264-016-0432-Y

The cost-effectiveness of drug regulation: the example of thorough QT/QTc studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40264-016-0432-Y

Willingness to pay for adverse drug event regulatory actions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40264-016-0432-Y

Sentinel site active surveillance of safety of first-line antiretroviral medicines in Namibia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40264-016-0432-Y

Highly active antiretroviral treatment and health related quality of life in South African adults with human immunodeficiency virus infection: A cross-sectional analytical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40264-016-0432-Y

Quality of life and the impact of drug toxicities in a South African community-based antiretroviral programme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40264-016-0432-Y

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40264-016-0432-Y

Physical and emotional health outcomes after 12 months of public-sector antiretroviral treatment in the Free State Province of South Africa: a longitudinal study using structural equation modelling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40264-016-0432-Y

Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40264-016-0432-Y

An assessment of adverse drug reactions among HIV positive patients receiving antiretroviral treatment in South Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40264-016-0432-Y

Cost and cost-effectiveness of switching from stavudine to tenofovir in first-line antiretroviral regimens in South Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40264-016-0432-Y

Do active surveillance and contact precautions reduce MRSA acquisition? A prospective interrupted time series

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40264-016-0432-Y

Epidemiological and Surveillance Response to Ebola Virus Disease Outbreak in Lofa County, Liberia (March-September, 2014); Lessons Learned

21 January 2018

1 reference

12 December 2020

HAART induced adverse drug reactions: A retrospective analysis at a tertiary referral health care center in India

1 reference

12 December 2020

Global pharmacovigilance for antiretroviral drugs: Overcoming contrasting priorities

1 reference

12 December 2020

Patient retention in antiretroviral therapy programs up to three years on treatment in sub-Saharan Africa, 2007-2009: systematic review

1 reference

12 December 2020

A framework for assessing the economic value of pharmacovigilance in low- and middle-income countries

1 reference

12 December 2020

Value for money of drug regulation

1 reference

12 December 2020

The cost-effectiveness of periodic safety update reports for biologicals in Europe

1 reference

12 December 2020

Cost-effectiveness of antiretroviral regimens in the World Health Organization's treatment guidelines: a South African analysis

1 reference

12 December 2020

10.1007/S40264-016-0432-Y

Identifiers

DOI

1 reference

release_ehtpnloytzbfzjf4igrgyao2oe

13 September 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ehtpnloytzbfzjf4igrgyao2oe

24 November 2022

mapped directly with Wikidata item

1 reference